Showing results (1-10 of 80) with videos related to
Sort By:
Pageof 8
Cancer Journal (Sudbury, Mass.)|March 25, 2024
Current Role and Status for Intratumoral Injection Therapies in Metastatic MelanomaAlexandra M Haugh, Adil I DaudThe Journal of Clinical Investigation|October 15, 2024
Distinguishing between help and harm: Helper T cell subsets and immune-related adverse eventsAlexandra M Haugh, Adil I DaudCancer Journal (Sudbury, Mass.)|January 24, 2017
Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These DrugsKimberly Loo, Adil I DaudCancer Control : Journal of the Moffitt Cancer Center|July 7, 2007
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitorsJade Homsi, Adil I DaudAmerican Journal of Clinical Dermatology|February 8, 2024
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous MelanomaAlexandra Haugh, Adil I DaudJournal of Hematology & Oncology|November 1, 2015
Nivolumab plus ipilimumab in the treatment of advanced melanomaKaty K Tsai, Adil I DaudExpert Opinion on Investigational Drugs|October 12, 2011
Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanomaPamela N Munster, Adil I DaudDrugs|March 25, 2015
The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to DateKaty K Tsai, Adil I DaudHuman Vaccines & Immunotherapeutics|May 13, 2022
Intratumoral therapies and in-situ vaccination for melanomaLaura A Huppert, Adil I DaudSeminars in Cutaneous Medicine and Surgery|July 25, 2018
Immunotherapy for melanomaLauren M Cuevas, Adil I DaudPageof 8